Showing results (141-150 of 156) with videos related to
Sort By:
Pageof 16
Communications Biology|June 10, 2022
Distinct dissociation rates of murine and human norovirus P-domain dimers suggest a role of dimer stability in virus-host interactionsRobert Creutznacher, Thorben Maass, Jasmin Dülfer, et al.Plos One|January 23, 2016
Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-StudyPatricia Hafner, Ulrike Bonati, Beat Erne, et al.Biomacromolecules|August 4, 2018
Fucose-Functionalized Precision Glycomacromolecules Targeting Human Norovirus Capsid ProteinKatharina Susanne Bücher, Hao Yan, Robert Creutznacher, et al.Plos Pathogens|August 23, 2012
Structures of Merkel cell polyomavirus VP1 complexes define a sialic acid binding site required for infectionUrsula Neu, Holger Hengel, Bärbel S Blaum, et al.Cell|April 24, 2007
Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptideJan Münch, Ludger Ständker, Knut Adermann, et al.Journal of General Internal Medicine|April 14, 2026
Does Checklist-Guided Shared Decision Making Have a Sustained Effect on Code Status Decisions Among Medical Inpatients? Long-Term Follow Up of the Randomized CLEAR Checklist TrialBenjamin Bissmann, Samuel K Zumbrunn, Sebastian Gross, et al.The Journal of Allergy and Clinical Immunology|August 10, 2016
β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasisFrank Kolbinger, Christian Loesche, Marie-Anne Valentin, et al.Nature Medicine|January 6, 2026
Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trialBeth Borowsky, Harry Ramos, Angelika Caputo, et al.The Journal of Allergy and Clinical Immunology|May 26, 2026
Early intervention with secukinumab prevents epigenetic scar development in new-onset psoriasis - STEPIn Mechanistic Sub-study resultsJohann E Gudjonsson, Katharina Bier, Swann Gaulis, et al.The Journal of Allergy and Clinical Immunology|May 27, 2019
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasisJames G Krueger, Keith A Wharton, Thomas Schlitt, et al.Pageof 16